1. Comprehensive investigation of clinicopathological and immunological features to determine prognostic impact in metastatic renal cell carcinoma: The JEWEL study
   Kojiro Ohba et al, 2023, International Journal of Urology CrossRef
2. Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
   Ondrej Fiala et al, 2020, Cancers CrossRef
3. Cost-effectiveness Analysis of Sunitinib and Sorafenib Sequential Treatment of Metastatic Renal Cell Carcinoma
   Toshihiro Shida et al, 2017, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) CrossRef
4. Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis
   Aleksandra Semeniuk-Wojtaś et al, 2018, Clinical Genitourinary Cancer CrossRef
5. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis
   Zhun Wang et al, 2017, Clinica Chimica Acta CrossRef
6. Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors
   Kenji Omae et al, 2017, Urologic Oncology: Seminars and Original Investigations CrossRef
7. Association between a novel nutrition‐inflammation prognostic grading system and overall survival in hospitalized adults with cancer: A retrospective cohort study
   Jia‐Xin Huang et al, 2024, Journal of Parenteral and Enteral Nutrition CrossRef
8. Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan
   Hideaki Miyake et al, 2016, Targeted Oncology CrossRef
9. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus
   S. Vázquez Estévez et al, 2020, Clinical and Translational Oncology CrossRef
10. Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan
    Kenichi Harada et al, 2019, International Journal of Urology CrossRef
11. Pharmacotherapies for renal cell carcinoma in Japan
    Kazuhiro Yoshimura et al, 2016, International Journal of Urology CrossRef
12. Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
    Mototsugu Oya et al, 2017, Cancer Science CrossRef
13. Clinical Decision Analysis of First-line Regimens for Advanced Recurrent Renal Cell Carcinoma
    Toshihiro Shida et al, 2017, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) CrossRef